{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:28:09Z","timestamp":1784068089973,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10928-025-09996-1","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T11:54:30Z","timestamp":1756554870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer\u2019s Disease: A mixed-effects disease progression model"],"prefix":"10.1007","volume":"52","author":[{"given":"Carson","family":"Essenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"9996_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fnagi.2014.00047","volume":"6","author":"D Ferreira","year":"2014","unstructured":"Ferreira D, Perestelo-Perez L, Westman E, Wahlund L-o, Sarria A, Serrano-Aguilar P (2014) Meta-review of CSF core biomarkers in Alzheimer\u2019s disease: The state-of-the-art after the new revised diagnostic criteria review. Front Aging Neurosci 6:47. https:\/\/doi.org\/10.3389\/fnagi.2014.00047","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"9996_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2005.06.003","volume":"1","author":"SG Mueller","year":"2005","unstructured":"Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L (2005) Ways toward an early diagnosis in Alzheimer\u2019s disease: The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Alzheimer\u2019s & Dementia 1(1):55\u201366. https:\/\/doi.org\/10.1016\/j.jalz.2005.06.003","journal-title":"Alzheimer's & Dementia"},{"issue":"3","key":"9996_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):280\u2013292. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003","journal-title":"Alzheimers Dement"},{"issue":"1","key":"9996_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s44202-022-00031-9","volume":"2","author":"SL Warren","year":"2022","unstructured":"Warren SL, Reid E, Whitfield P, Moustafa AA (2022) Subjective memory complaints as a predictor of mild cognitive impairment and Alzheimer\u2019s disease. Discov Psychol 2(1):13. https:\/\/doi.org\/10.1007\/s44202-022-00031-9","journal-title":"Discov Psychol"},{"key":"9996_CR5","doi-asserted-by":"publisher","first-page":"685636","DOI":"10.3389\/fneur.2022.685636","volume":"13","author":"S-Y Lin","year":"2022","unstructured":"Lin S-Y, Lin P-C, Lin Y-C et al (2022) The clinical course of early and late mild cognitive impairment. Front Neurol 13:685636. https:\/\/doi.org\/10.3389\/fneur.2022.685636","journal-title":"Front Neurol"},{"key":"9996_CR6","doi-asserted-by":"crossref","unstructured":"L\u00f3pez OL, DeKosky ST. Clinical symptoms in Alzheimer's disease. Handbook of Clinical Neurology. Elsevier; 2008:207\u2013216","DOI":"10.1016\/S0072-9752(07)01219-5"},{"issue":"6","key":"9996_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8(6):595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210","journal-title":"EMBO Mol Med"},{"issue":"5","key":"9996_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0197-4580(01)00271-8","volume":"22","author":"BC Dickerson","year":"2001","unstructured":"Dickerson BC, Goncharova I, Sullivan MP et al (2001) MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer\u2019s disease. Neurobiol Aging 22(5):747\u2013754. https:\/\/doi.org\/10.1016\/S0197-4580(01)00271-8","journal-title":"Neurobiol Aging"},{"issue":"6","key":"9996_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/brain\/119.6.2001","volume":"119","author":"NC Fox","year":"1996","unstructured":"Fox NC, Warrington EK, Freeborough PA et al (1996) Presymptomatic hippocampal atrophy in Alzheimer\u2019s disease: A longitudinal MRI study. Brain 119(6):2001\u20132007. https:\/\/doi.org\/10.1093\/brain\/119.6.2001","journal-title":"Brain"},{"issue":"4","key":"9996_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I","volume":"47","author":"RJ Killiany","year":"2000","unstructured":"Killiany RJ, Gomez-Isla T, Moss M et al (2000) Use of structural magnetic resonance imaging to predict who will get Alzheimer\u2019s disease. Ann Neurol 47(4):430\u2013439. https:\/\/doi.org\/10.1002\/1531-8249(200004)47:4%3c430::AID-ANA5%3e3.0.CO;2-I","journal-title":"Ann Neurol"},{"key":"9996_CR11","doi-asserted-by":"publisher","first-page":"769982","DOI":"10.3389\/fncom.2021.769982","volume":"15","author":"SH Hojjati","year":"2022","unstructured":"Hojjati SH, Babajani-Feremi A, Alzheimer\u2019s Disease Neuroimaging Initiative (2022) Prediction and modeling of neuropsychological scores in Alzheimer\u2019s disease using multimodal neuroimaging data and artificial neural networks. Front Computational Neurosci 15:769982. https:\/\/doi.org\/10.3389\/fncom.2021.769982","journal-title":"Front Computational Neurosci"},{"issue":"3","key":"9996_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1001\/archneur.63.3.431","volume":"63","author":"JR Murrell","year":"2006","unstructured":"Murrell JR, Price B, Lane KA et al (2006) Association of Apolipoprotein E Genotype and Alzheimer disease in african americans. Arch Neurol 63(3):431\u2013434. https:\/\/doi.org\/10.1001\/archneur.63.3.431","journal-title":"Arch Neurol"},{"issue":"5","key":"9996_CR13","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, Saunders AM, Schmechel D et al (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90(5):1977\u20131981. https:\/\/doi.org\/10.1073\/pnas.90.5.1977","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"9996_CR14","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D et al (2024) APOE4 homozygozity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med 30(5):1284\u20131291. https:\/\/doi.org\/10.1038\/s41591-024-02931-w","journal-title":"Nat Med"},{"issue":"12","key":"9996_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.NT.0001025440.05254.14","volume":"24","author":"G Shaw","year":"2024","unstructured":"Shaw G (2024) New study characterizing APOE4 homozygosity as distinct form of Alzheimer\u2019s Sparks Debate. Neurol Today 24(12):1\u20139","journal-title":"Neurol Today"},{"key":"9996_CR16","unstructured":"ADNIMERGE: Alzheimer\u2019s disease neuroimaging initiative. Version R package version 0.0.1. 2023."},{"issue":"4","key":"9996_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/cpt.2987","volume":"114","author":"G Singh","year":"2023","unstructured":"Singh G, Ramanathan M (2023) Repurposing artificial intelligence tools for disease modeling: Case study of face recognition deficits in neurodegenerative diseases. Clin Pharmacol Ther 114(4):862\u2013873. https:\/\/doi.org\/10.1002\/cpt.2987","journal-title":"Clin Pharmacol Ther"},{"key":"9996_CR18","unstructured":"R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2022. https:\/\/www.R-project.org\/"},{"issue":"1","key":"9996_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.32614\/RJ-2021-041","volume":"13","author":"RA Peterson","year":"2021","unstructured":"Peterson RA (2021) Finding optimal normalizing transformations via bestNormalize. The R Journal 13(1):310\u2013329. https:\/\/doi.org\/10.32614\/RJ-2021-041","journal-title":"The R Journal"},{"issue":"1","key":"9996_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker BM, Walker SC (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67(1):1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01","journal-title":"J Stat Softw"},{"issue":"3","key":"9996_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1017\/S1355617707070506","volume":"13","author":"M Rohit","year":"2007","unstructured":"Rohit M, Levine A, Hinkin C et al (2007) Education correction using years in school or reading grade-level equivalent? Comparing the accuracy of two methods in diagnosing HIV-associated neurocognitive impairment. J Int Neuropsychol Soc 13(3):462\u2013470. https:\/\/doi.org\/10.1017\/S1355617707070506","journal-title":"J Int Neuropsychol Soc"},{"issue":"26","key":"9996_CR22","doi-asserted-by":"publisher","first-page":"772","DOI":"10.21105\/joss.00772","volume":"3","author":"D L\u00fcdecke","year":"2018","unstructured":"L\u00fcdecke D (2018) Ggeffects Tidy data frames of marginal effects from regression models. J Open Source Softw 3(26):772","journal-title":"J Open Source Softw"},{"issue":"60","key":"9996_CR23","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.21105\/joss.03139","volume":"6","author":"D L\u00fcdecke","year":"2021","unstructured":"L\u00fcdecke D, Ben-Shachar MS, Patil I, Waggoner P, Makowski D (2021) Performance: An R Package for assessment, comparison and testing of statistical models. J Open Source Software 6(60):3139","journal-title":"J Open Source Software"},{"issue":"5","key":"9996_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0091270011405497","volume":"52","author":"MN Samtani","year":"2012","unstructured":"Samtani MN, Farnum M, Lobanov V et al (2012) An improved model for disease progression in patients from the Alzheimer\u2019s disease neuroimaging initiative. J Clin Pharmacol 52(5):629\u2013644. https:\/\/doi.org\/10.1177\/0091270011405497","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9996_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2125.2012.04308.x","volume":"75","author":"MN Samtani","year":"2013","unstructured":"Samtani MN, Raghavan N, Shi Y et al (Jan2013) Disease progression model in subjects with mild cognitive impairment from the Alzheimer\u2019s disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br J Clin Pharmacol 75(1):146\u2013161. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04308.x","journal-title":"Br J Clin Pharmacol"},{"key":"9996_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2147\/NDT.S62323","volume":"10","author":"MN Samtani","year":"2014","unstructured":"Samtani MN, Raghavan N, Novak G, Nandy P, Narayan VA (2014) Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer\u2019s subjects from the Alzheimer\u2019s Disease Neuroimaging Initiative. Neuropsychiatr Dis Treat 10:929\u2013952. https:\/\/doi.org\/10.2147\/NDT.S62323","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"9996_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jalz.2010.03.018","volume":"7","author":"K Ito","year":"2011","unstructured":"Ito K, Corrigan B, Zhao Q et al (2011) Disease progression model for cognitive deterioration from Alzheimer\u2019s Disease Neuroimaging Initiative database. Alzheimers Dement 7(2):151\u2013160. https:\/\/doi.org\/10.1016\/j.jalz.2010.03.018","journal-title":"Alzheimers Dement"},{"issue":"12","key":"9996_CR28","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1002\/alz.14346","volume":"20","author":"SP Schauer","year":"2024","unstructured":"Schauer SP, Toth B, Lee J et al (2024) Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer\u2019s disease pathophysiology. Alzheimers Dement 20(12):8855\u20138866. https:\/\/doi.org\/10.1002\/alz.14346","journal-title":"Alzheimers Dement"},{"issue":"7","key":"9996_CR29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/psp4.12974","volume":"12","author":"S Jamalian","year":"2023","unstructured":"Jamalian S, Dolton M, Chanu P et al (2023) Modeling Alzheimer\u2019s disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB. CPT Pharmacometrics Syst Pharmacol 12(7):1029\u20131042. https:\/\/doi.org\/10.1002\/psp4.12974","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"9996_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/psp4.12876","volume":"12","author":"V Ramakrishnan","year":"2023","unstructured":"Ramakrishnan V, Friedrich C, Witt C et al (2023) Quantitative systems pharmacology model of the amyloid pathway in Alzheimer\u2019s disease: Insights into the therapeutic mechanisms of clinical candidates. CPT Pharmacometrics Syst Pharmacol 12(1):62\u201373. https:\/\/doi.org\/10.1002\/psp4.12876","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"9996_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10928-024-09959-y","volume":"52","author":"ME Elhefnawy","year":"2025","unstructured":"Elhefnawy ME, Patson N, Mouksassi S et al (2025) Quantifying natural amyloid plaque accumulation in the continuum of Alzheimer\u2019s disease using ADNI. J Pharmacokinet Pharmacodyn 52(1):15. https:\/\/doi.org\/10.1007\/s10928-024-09959-y","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9996_CR32","doi-asserted-by":"publisher","unstructured":"Delor I, Charoin JE, Gieschke R, Retout S, Jacqmin P (2013) Modeling Alzheimer\u2019s Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI. CPT Pharmacometrics Syst Pharmacol 2(10). https:\/\/doi.org\/10.1038\/psp.2013.54","DOI":"10.1038\/psp.2013.54"},{"issue":"5123","key":"9996_CR33","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261(5123):921\u2013923. https:\/\/doi.org\/10.1126\/science.8346443","journal-title":"Science"},{"issue":"9","key":"9996_CR34","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/mp.2011.52","volume":"16","author":"E Genin","year":"2011","unstructured":"Genin E, Hannequin D, Wallon D et al (2011) APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16(9):903\u2013907. https:\/\/doi.org\/10.1038\/mp.2011.52","journal-title":"Mol Psychiatry"},{"issue":"5\u20136","key":"9996_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00702-022-02461-0","volume":"129","author":"GS Benson","year":"2022","unstructured":"Benson GS, Bauer C, Hausner L et al (2022) Don\u2019t forget about tau: the effects of ApoE4 genotype on Alzheimer\u2019s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network. J Neural Transm (Vienna) 129(5\u20136):477\u2013486. https:\/\/doi.org\/10.1007\/s00702-022-02461-0","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"9996_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C-C Liu","year":"2013","unstructured":"Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106\u2013118. https:\/\/doi.org\/10.1038\/nrneurol.2012.263","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"9996_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/2229-3485.179436","volume":"7","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Pramesh CS, Buyse M (2016) Common pitfalls in statistical analysis: The perils of multiple testing. Perspect Clin Res Apr-Jun 7(2):106\u2013107. https:\/\/doi.org\/10.4103\/2229-3485.179436","journal-title":"Perspect Clin Res Apr-Jun"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09996-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-09996-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09996-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:33:16Z","timestamp":1761154396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-09996-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["9996"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-09996-1","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study used publicly available data. Consent was not necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}